Vol 6 (2021): Continuous Publishing
Original paper
Published online: 2021-12-30

open access

Page views 5621
Article views/downloads 497
Get Citation

Connect on Social Media

Connect on Social Media

Effects of prophylactic use of brimonidine 0.2% on intraocular pressure after YAG-capsulotomy

Tayyaba Gul Malik1, Aalia Ali2, Syed Abdullah Mazhar2, Rabail Alam3
Ophthalmol J 2021;6:265-269.


Background: Rise in intraocular pressure (IOP) is the commonest complication after YAG posterior capsulotomy. As there are different opinions regarding use of anti-glaucoma therapy before YAG, we compared post-YAG IOP between the patients who had Brimonidine eye drops and those who did not have any anti-glaucoma treatment.

Material and methods: It was a prospective study that included patients who had undergone uneventful phacoemulsification with foldable intraocular lens implantation and YAG posterior capsulotomy. One hundred fifty patients were divided into two groups; (a group with prophylactic brimonidine 0.2% eye drops before laser and a group without any anti-glaucoma therapy). Intraocular pressure was checked pre-laser and one hour after laser procedure.

Results: Out of 150 patients, 78 were in brimonidine group and 72 in the control group. The mean age of the patients was 60.39 ± 12.98 years. In the brimonidine group, IOP was 12.56 ± 2.38 mm Hg and 12.29 ± 3.64 mm Hg before and after YAG, respectively. In the control group, IOP was 12.24 ± 1.53 mm Hg and 13.38 ± 2.84 mm Hg before and after YAG. Brimonidine 0.2% caused a decrease in IOP, but the post-laser IOP difference between the two groups was not statistically significant. The change in IOP before and after using brimonidine 0.2% was also not statistically significant.

Conclusion: Every patient undergoing YAG capsulotomy does not require prophylactic anti-glaucoma therapy. Only the patients prone to high IOP, glaucoma suspects, and diagnosed cases of glaucoma should be given prophylactic treatment.

Article available in PDF format

View PDF Download PDF file


  1. MacEwen CJ, Dutton GN. Neodymium-YAG laser in the management of posterior capsular opacification--complications and current trends. Trans Ophthalmol Soc U K. 1986; 105 ( Pt 3): 337–344.
  2. Lin JC, Katz LJ, Spaeth GL, et al. Intraocular pressure control after Nd:YAG laser posterior capsulotomy in eyes with glaucoma. Br J Ophthalmol. 2008; 92(3): 337–339.
  3. Minello AA, Prata Junior JA, Mello PA. [Efficacy of topic ocular hipotensive agents after posterior capsulotomy]. Arq Bras Oftalmol. 2008; 71(5): 706–710.
  4. Shani L, David R, Tessler Z, et al. Intraocular pressure after neodymium:YAG laser treatments in the anterior segment. J Cataract Refract Surg. 1994; 20(4): 455–458.
  5. Ari S, Cingü AK, Sahin A, et al. The effects of Nd:YAG laser posterior capsulotomy on macular thickness, intraocular pressure, and visual acuity. Ophthalmic Surg Lasers Imaging. 2012; 43(5): 395–400.
  6. Thiab HH. Changes in intraocular pressure after ND-yag laser posterior capsulotomy. Int J Clin Exp Ophthalmol. 2020; 4(1): 021–030.
  7. Parajuli A, Joshi P, Subedi P, et al. Effect of Nd:YAG laser posterior capsulotomy on intraocular pressure, refraction, anterior chamber depth, and macular thickness. Clin Ophthalmol. 2019; 13: 945–952.
  8. Karahan E, Tuncer I, Zengin MO. The Effect of ND:YAG Laser Posterior Capsulotomy Size on Refraction, Intraocular Pressure, and Macular Thickness. J Ophthalmol. 2014; 2014: 846385.
  9. Achiron A. Intraocular Pressure Spikes following Neodymium-doped Yttrium Aluminum Garnet Laser Capsulotomy: Current Prevalence and Management in Israel. J Curr Glaucoma Pract. 2017; 11(2): 63–66.
  10. Nesher R, Kolker AE. Failure of apraclonidine to prevent delayed IOP elevation after Nd:YAG laser posterior capsulotomy. Trans Am Ophthalmol Soc. 1990; 88: 229–232 (discussion 233–236).
  11. Chen TC, Ang RT, Grosskreutz CL, et al. Brimonidine 0.2% versus apraclonidine 0.5% for prevention of intraocular pressure elevations after anterior segment laser surgery. Ophthalmology. 2001; 108(6): 1033–1038.
  12. Rao CMS, Satyasrinivas V, Muralikrishna V, et al. Clinical Study of Visual Outcome and Intraocular Pressure Changes Following Neodymium-doped Yttrium Aluminum Garnet Laser Capsulotomy in Post-operative Cataract Patients with Posterior Capsule Opacification. . Intern J Sci Study. 2017; 5: 76–82.
  13. Singhal D, Desai R, Desai S, et al. Use of topical brimonidine to prevent intraocular pressure elevations following Nd: YAG-laser posterior capsulotomy. J Pharmacol Pharmacother. 2011; 2(2): 104–106.
  14. Seong GJ, Lee YG, Lee JH, et al. Effect of 0.2% brimonidine in preventing intraocular pressure elevation after Nd:YAG laser posterior capsulotomy. Ophthalmic Surg Lasers. 2000; 31(4): 308–314.
  15. Calli U. The effect of prophylactic topical brimonidine on intraocular pressure after Nd: YAG laser posterior capsulotomy. J Kartal Train Res Hosp. 2016.
  16. Saleem M, Manzoor M, Shehzad A, et al. Brimonidine efficacy on intraocular pressure control following ND: YAG laser capsulotomy. Pak Armed Forces Med J. 2018; 68(2): 245–249.
  17. Niazi M, Rauf A, Nadeem Y. Brimonidine for Prevention of Intraocular Pressure Elevation after YAG-Posterior Capsulotomy. Pak J Ophthalmol. 2020; 36(2).
  18. Yellamelli A, Baldev V, Batra N, et al. Effect of topical brimonidine 0.15% versus timolol 0.5% to prevent intraocular pressure elevation after nd: yag laser capsulotomy. J Evid Based Med Healthc. 2017; 4(55): 3365–3368.
  19. Manandhar LD, Gurung N, Shrestha K, et al. Study of Intraocular Pressure following Neodynium Yttrium Aluminium Garnet Laser Capsulotomy with the Use of Brimonidine: A Descriptive Cross-sectional Study. JNMA J Nepal Med Assoc. 2021; 59(233): 15–18.
  20. Murtaza B, Hussain AW, Haq AU, et al. Changes in intraocular pressure following high energy Nd-Yag laser posterior capsulotomy. Pak Armed Forces Med J. 2018; 68: 872–875.